Axonics receives ce mark approval for fourth-generation rechargeable sacral neuromodulation system

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the axonics r20™ rechargeable sacral neuromodulation (snm) system has received ce mark approval. the r20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once.
AXNX Ratings Summary
AXNX Quant Ranking